A new B.C.-led evidence roundup weighs when take-home doses should start, what caregivers of children with obesity actually want, and how well HPV vaccines are holding up in three Canadian cities.
Timing may matter as much as access when it comes to take-home methadone, according to a new analysis of more than 41,000 Canadian patients published in JAMA Internal Medicine on September 8, 2026. The study, led by researchers at Vancouver’s Centre for Advancing Health Outcomes, found that patients who began take-home dosing after completing their opioid agonist treatment induction had better survival and stayed in treatment longer — with the strongest signal among those who started between five and 24 weeks in.
The finding was published alongside two other Canadian studies in the Centre’s September 2026 research roundup: one on what caregivers of children with obesity say they need from the health system, and one measuring anal HPV prevalence and vaccine benefit among 1,519 gay, bisexual and other men who have sex with men in Montreal, Toronto and Vancouver.
What the JAMA Internal Medicine Analysis Actually Measured
Methadone is a long-standing treatment for opioid use disorder, and in most Canadian settings the daily dose is taken under observation at a pharmacy. Take-home doses — often called carries — are made available once a prescriber judges a patient to be stable, with ongoing reassessment.
The research team, including Dr. Belal Hossain, Jeong Eun Min, Megan Kurz, Dr. Ehsan Karim and Dr. Bohdan Nosyk, set out to test whether the timing of that transition was associated with mortality and treatment discontinuation. Two groups were analysed: 9,788 incident methadone users with no history of opioid agonist treatment (OAT), and 31,658 prevalent new users who had not received OAT in the previous month.
All participants had completed OAT induction, defined in the study as two weeks of continuous treatment with no changes to the OAT dose. From there, each person fell into one of four categories: first take-home dose within 0–4 weeks of induction, within 5–12 weeks, within 13–24 weeks, or no take-home dosing at all.
Why the 5-12 and 13-24 Week Windows Stood Out
Across the cohort, initiating take-home methadone was associated with improved survival and better treatment retention compared with not initiating it. But the effect was not uniform across the four windows. The improvement was particularly evident among patients who started take-home dosing 5–12 weeks and 13–24 weeks after induction.
That nuance is the practical heart of the paper. It suggests the question facing prescribers is not simply whether a patient should receive carries, but when the transition is most likely to help — a distinction that has been debated in clinical circles for years, often with limited population-level evidence to draw on.
The study is observational, not a randomised trial, so it describes associations rather than proving cause and effect. Decisions about take-home dosing remain clinical judgments made by prescribers under provincial treatment guidelines, and patients should not alter any treatment plan based on a single published study.
Where Take-Home Methadone Fits in Canada’s Opioid Response
Take-home dosing sits at a familiar tension point in addiction medicine. Witnessed dosing is intended to reduce risks such as diversion and unintentional overdose, but it also requires daily pharmacy attendance — a real barrier for people who work, live far from a dispensing site, or face mobility and transportation challenges. Carries reduce that burden, which is one reason retention improves.
Provincial clinical guidance in British Columbia already sets out criteria for assessing stability before take-home doses are granted and for reassessing them over time. What this analysis adds is population-scale evidence on sequencing, giving guideline committees and prescribers something more specific than a binary yes-or-no framing.
For policymakers, the relevance is straightforward: retention in OAT is one of the few levers consistently linked to lower mortality during Canada’s ongoing toxic drug crisis. Evidence that the timing of a routine clinical decision is associated with survival is the kind of finding that tends to surface in the next round of guideline updates.
What 108 Caregivers Said About Managing Pediatric Obesity
The second study in the roundup, published in the Journal of Pediatric Nursing (2026;91:672-680), turned to families. Roughly 30% of children in Canada are living with overweight or obesity, a pattern associated with elevated risk of conditions including type 2 diabetes and cardiovascular disease.
Centre scientist Dr. Josie Geller and colleagues used a convergent mixed-methods design to ask 108 caregivers of children aged 6–17 with a BMI at or above the 97th percentile two questions: which topics matter most in pediatric obesity management, and what they expect from family navigation, a model in which navigators provide education, emotional support and help accessing care.
- Knowledge over skills: Caregivers placed higher value on knowledge about nutrition and physical activity than on skills training in those areas.
- Appointments are about behaviour change: Families said they attend clinic visits primarily to get support with changing behaviour.
- Scheduling is the sticking point: Regular attendance was difficult for many caregivers because of scheduling conflicts.
- Monthly contact preferred: Participants wanted to meet with a family navigator at least once a month.
- Navigator as connector: Caregivers defined the navigator’s role as linking families to community resources and appropriate health care providers to support behaviour change and improve children’s health.
Anal HPV Prevalence Across Montreal, Toronto and Vancouver
The third study, published online in the Journal of Infectious Diseases on August 26, 2026, examined how well HPV vaccination is translating into lower infection rates in a population at elevated risk. High-risk HPV types account for more than 90% of anal cancers, a cancer that most commonly affects gay, bisexual and other men who have sex with men (GBM).
Centre scientist Dr. Troy Grennan and a national team assessed anal HPV prevalence among 1,519 adult GBM in Montreal, Toronto and Vancouver between 2019 and 2021, breaking results down by age, years of sexual activity before vaccination, and HIV status.
Vaccination Coverage Dropped Sharply With Age
Coverage varied widely by age group within the cohort:
| Age group | Had received HPV vaccination |
|---|---|
| 16–26 years | 62% |
| 27–45 years | 40% |
| 46 years and older | 15% |
Vaccine-preventable anal HPV types were less prevalent among participants aged 23 and younger who had received their first dose at least three years earlier and had five or fewer years of sexual activity before vaccination — a pattern that held regardless of HIV status. Vaccine-preventable anal HPV was also less common among vaccinated GBM in the older age groups, though the difference there was smaller.
The practical reading is one that public health programs have made before in other contexts: vaccination appears to deliver its clearest benefit when given earlier and before extended sexual activity, while still showing measurable, if more modest, benefit later.
The Common Thread: Small Timing Decisions With Large Downstream Effects
Read together, the three papers circle the same practical question from different directions. In the methadone analysis, the variable is when carries begin. In the HPV study, it is how early a vaccine is given relative to sexual activity. In the pediatric obesity work, it is how often families can realistically reach a navigator — monthly, by their own account — and whether appointment scheduling accommodates working caregivers.
None of these are questions about whether an intervention works. They are questions about sequencing and access, which is where a growing share of Canadian health services research is now concentrated. For readers following health policy, that shift is worth noting: the debate is moving from what to fund toward how and when to deliver it.
The Centre for Advancing Health Outcomes, based at St. Paul’s Hospital in Vancouver, publishes its Evidence Speaks roundup on a recurring basis, summarising selected peer-reviewed work from its researchers for media and the wider research community. The September 2026 edition was posted on September 22.
Frequently Asked Questions
What does “OAT induction” mean in the methadone study?
The researchers defined completed induction as two weeks of continuous opioid agonist treatment with no changes to the OAT dose. The timing windows for take-home dosing were measured from that point.
Does the study prove that delaying take-home doses causes better outcomes?
No. It is an observational analysis of administrative data and reports associations. Starting take-home methadone was associated with improved survival and retention, most strongly in the 5–12 and 13–24 week windows, but causation is not established by this design.
How large was the study population?
It included 9,788 incident methadone users with no prior OAT history and 31,658 prevalent new users who had not received OAT in the preceding month.
Were the HPV findings the same for participants living with HIV?
Yes for the youngest group. Lower prevalence of vaccine-preventable anal HPV among those aged 23 and under who were vaccinated at least three years earlier held regardless of HIV status.
The Brand Magazine Newsroom covers Canadian business, markets and policy news for brand builders and entrepreneurs. Newsroom reports are produced from published public sources such as company releases and government and regulator publications, and follow our Editorial Standards.
